logo

Granisetron Market Size (2024 - 2029)

The granisetron market is anticipated to experience significant growth during the forecast period, driven by an increase in chemotherapy and radiotherapy visits and a rising prevalence of gastroparesis. The demand for granisetron is largely attributed to its effectiveness in treating chemotherapy-induced vomiting, a common side effect of cancer treatments. Clinical trials and research studies are further supporting the expansion of the market by demonstrating the drug's efficacy in various conditions, including its use in pediatric patients. Despite these positive trends, potential adverse effects of granisetron may pose challenges to market growth.

Home Market Analysis Healthcare Research Pharmaceuticals Research Active Pharmaceutical Ingredients Research General Pharmaceuticals Research Antiemetics Research Granisetron Market Market Size

Market Size of Granisetron Industry

Granisetron Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
CAGR (2024 - 2029) 6.20 %
Fastest Growing Market Asia-Pacific
Largest Market North America

Major Players

Granisetron Market Major Players

*Disclaimer: Major Players sorted in no particular order

Granisetron Market Analysis

The Granisetron Market is expected to register a CAGR of 6.20% during the forecast period.

The key factors propelling market growth are the rise in chemotherapy and radiotherapy visits, along with the increasing prevalence of gastroparesis. The rising burden of cancer is expected to propel chemotherapy and radiotherapy visits, which can ultimately cause chemotherapy-induced vomiting, subsequently creating demand for granisetron. 

Chemotherapy drugs frequently induce nausea and vomiting. These symptoms can manifest after treatment commences, lasting for 24 to 48 hours. However, for some individuals, the discomfort can persist for as long as seven days post-treatment. Various research studies have demonstrated the importance of granisetron in the treatment of chemotherapy-induced vomiting. For instance, as per the article published in June 2024 in the Lung Cancer journal, researchers showed that prophylactic treatment combining mirtazapine with granisetron and dexamethasone demonstrates promising efficacy and a favorable safety profile for carboplatin (CBDCA)-induced nausea and vomiting in patients with thoracic cancers.

Furthermore, various clinical trials have been conducted worldwide to understand the effectiveness of granisetron in various conditions. For instance, in September 2023, Ain Shams University sponsored a clinical trial to evaluate the efficacy of granisetron versus ondansetron for nausea and vomiting in the pediatric age group. Thus, studies evaluating the efficacies of treating nausea and vomiting are expected to boost the administration of granisetron, which is expected to fuel market growth.

Thus, due to the abovementioned factors, the market studied is expected to grow significantly during the forecast period. However, the adverse effects of granisetron are expected to hinder market growth.

Granisetron Industry Segmentation

As per the scope of the report, granisetron is a serotonin 5-HT3 receptor antagonist used as an antiemetic to treat nausea and vomiting following chemotherapy and radiotherapy. Its major effect is to reduce the activity of the vagus nerve, the nerve that activates the vomiting center in the medulla oblongata.

The granisetron market is segmented by product type, application, and geography. By product type, the market is segmented into transdermal, injection, and oral. By application, the market is segmented into chemotherapy and post-operative. By geography, the market is segmented into North America, Europe, Asia-Pacific, and Rest of the World. The report offers the value (USD) for the above segments.

By Product Type
Transdermal System
Injection
Oral
By Application
Chemotherapy
Post-operative
By Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Rest of the World
Need A Different Region Or Segment?
Customize Now

Granisetron Market Size Summary

The granisetron market is poised for significant growth, driven by the increasing incidence of cancer and the subsequent rise in chemotherapy and radiotherapy treatments. This surge in cancer cases has led to a higher demand for granisetron, a serotonin-3 receptor antagonist, to manage chemotherapy-induced nausea and vomiting. The market is further bolstered by the growing prevalence of gastroparesis, which also necessitates the use of granisetron. Research studies have highlighted the efficacy of granisetron in various settings, including its combination with other medications to enhance its effectiveness in preventing nausea and vomiting. Clinical trials continue to explore its potential across different demographics, such as pediatric patients, which is expected to further stimulate market expansion. Despite the promising growth prospects, the market faces challenges due to the potential adverse effects associated with granisetron.

Regionally, North America is anticipated to experience notable growth in the granisetron market, attributed to the high cancer burden and the increasing adoption of granisetron among patients undergoing chemotherapy and radiotherapy. The availability of various granisetron formulations, including injections and transdermal patches, enhances its accessibility and usage in managing cancer-induced vomiting. The market is characterized by a semi-consolidated structure, with key players like Kyowa Kirin Co. Ltd, Heron Therapeutics, and Fresenius SE & Co. KGaA actively engaging in strategic initiatives such as product launches and acquisitions to strengthen their market position. These activities, coupled with the ongoing research and development efforts, are expected to drive the growth of the granisetron market over the forecast period.

Explore More

Granisetron Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Rise in Chemotheraphy and Radiotherapy Visits

      2. 1.2.2 Increasing Incidence of Gastroparesis

    3. 1.3 Market Restraints

      1. 1.3.1 Adverse Effects of Granisetron

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD)

    1. 2.1 By Product Type

      1. 2.1.1 Transdermal System

      2. 2.1.2 Injection

      3. 2.1.3 Oral

    2. 2.2 By Application

      1. 2.2.1 Chemotherapy

      2. 2.2.2 Post-operative

    3. 2.3 By Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Mexico

      2. 2.3.2 Europe

        1. 2.3.2.1 Germany

        2. 2.3.2.2 United Kingdom

        3. 2.3.2.3 France

        4. 2.3.2.4 Italy

        5. 2.3.2.5 Spain

        6. 2.3.2.6 Rest of Europe

      3. 2.3.3 Asia-Pacific

        1. 2.3.3.1 China

        2. 2.3.3.2 Japan

        3. 2.3.3.3 India

        4. 2.3.3.4 Australia

        5. 2.3.3.5 South Korea

        6. 2.3.3.6 Rest of Asia-Pacific

      4. 2.3.4 Rest of the World

Granisetron Market Size FAQs

The Granisetron Market is projected to register a CAGR of 6.20% during the forecast period (2024-2029)

Kyowa Kirin Co., Ltd., Heron Therapeutics, Inc., Viatris, Hikma Pharmaceuticals PLC and Fresenius SE & Co. KGaA are the major companies operating in the Granisetron Market.

Granisetron Market Report Snapshots

Granisetron Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)